Roivant Sciences Ltd (ROIV) - Net Assets
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has net assets worth $4.97 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.23 Billion) and total liabilities ($251.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ROIV financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.97 Billion |
| % of Total Assets | 95.19% |
| Annual Growth Rate | 32.99% |
| 5-Year Change | 139.93% |
| 10-Year Change | N/A |
| Growth Volatility | 117.49 |
Roivant Sciences Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore ROIV asset base for the complete picture of this company's asset base.
Annual Net Assets for Roivant Sciences Ltd (2019–2025)
The table below shows the annual net assets of Roivant Sciences Ltd from 2019 to 2025. For live valuation and market cap data, see ROIV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $5.19 Billion | -19.56% |
| 2024-03-31 | $6.45 Billion | +301.13% |
| 2023-03-31 | $1.61 Billion | -22.02% |
| 2022-03-31 | $2.06 Billion | -4.65% |
| 2021-03-31 | $2.16 Billion | +2.53% |
| 2020-03-31 | $2.11 Billion | +124.98% |
| 2019-03-31 | $937.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Roivant Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 242579700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $116.06 Million | 2.48% |
| Other Comprehensive Income | $9.44 Million | 0.20% |
| Other Components | $4.56 Billion | 97.32% |
| Total Equity | $4.69 Billion | 100.00% |
Roivant Sciences Ltd Competitors by Market Cap
The table below lists competitors of Roivant Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Valterra Platinum Limited
JSE:VAL
|
$20.46 Billion |
|
Telefónica S.A
F:TNE2
|
$20.47 Billion |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
$20.48 Billion |
|
Bank of Nanjing Co Ltd
SHG:601009
|
$20.48 Billion |
|
Huatai Securities Co Ltd
SHG:601688
|
$20.44 Billion |
|
Baoshan Iron & Steel Co Ltd
SHG:600019
|
$20.43 Billion |
|
Jiangsu Zhongtian Technology Co Ltd
SHG:600522
|
$20.43 Billion |
|
Principal Financial Group Inc
NASDAQ:PFG
|
$20.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Roivant Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,968,581,000 to 4,687,605,000, a change of -1,280,976,000 (-21.5%).
- Net loss of 171,981,000 reduced equity.
- Share repurchases of 1,293,232,000 reduced equity.
- New share issuances of 112,782,000 increased equity.
- Other comprehensive income increased equity by 13,521,000.
- Other factors increased equity by 57,934,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-171.98 Million | -3.67% |
| Share Repurchases | $1.29 Billion | -27.59% |
| Share Issuances | $112.78 Million | +2.41% |
| Other Comprehensive Income | $13.52 Million | +0.29% |
| Other Changes | $57.93 Million | +1.24% |
| Total Change | $- | -21.46% |
Book Value vs Market Value Analysis
This analysis compares Roivant Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.58x to 4.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | $3.33 | $28.56 | x |
| 2020-03-31 | $2.97 | $28.56 | x |
| 2021-03-31 | $2.77 | $28.56 | x |
| 2022-03-31 | $2.47 | $28.56 | x |
| 2023-03-31 | $1.62 | $28.56 | x |
| 2024-03-31 | $7.18 | $28.56 | x |
| 2025-03-31 | $6.46 | $28.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Roivant Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -591.96%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.16x
- Recent ROE (-3.67%) is above the historical average (-28.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -145.33% | -44835.15% | 0.00x | 1.94x | $-1.11 Billion |
| 2020 | 59.08% | 1773.57% | 0.03x | 1.22x | $997.29 Million |
| 2021 | -42.64% | -3400.86% | 0.01x | 1.42x | $-999.01 Million |
| 2022 | -51.01% | -1528.89% | 0.02x | 1.56x | $-1.01 Billion |
| 2023 | -87.15% | -1646.59% | 0.03x | 2.06x | $-1.12 Billion |
| 2024 | 72.86% | 13294.18% | 0.00x | 1.21x | $3.75 Billion |
| 2025 | -3.67% | -591.96% | 0.01x | 1.16x | $-640.74 Million |
Industry Comparison
This section compares Roivant Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,806,965
- Average return on equity (ROE) among peers: -24.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Roivant Sciences Ltd (ROIV) | $4.97 Billion | -145.33% | 0.05x | $20.44 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $184.86 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $309.49 Million | -29.88% | 0.05x | $3.82 Billion |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more